{"id":65585,"date":"2023-09-26T08:39:57","date_gmt":"2023-09-26T12:39:57","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/astrazeneca-looks-to-china-for-growth\/"},"modified":"2023-09-26T08:39:59","modified_gmt":"2023-09-26T12:39:59","slug":"astrazeneca-looks-to-china-for-growth","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=65585","title":{"rendered":"AstraZeneca Looks To China For Growth"},"content":{"rendered":"<div>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">Key Takeaways<\/h2>\n<ul>\n<li>AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they\u2019re continuing to increase investment in the country<\/li>\n<li>Growing tensions between China and the US are making many companies nervous about their operations in China, and AstraZeneca is no exception<\/li>\n<li>They\u2019ve reportedly drawn up plans to split their Chinese operations and list in Hong Kong or Shanghai, but the company has shrugged this off as a \u201crumor\u201d.<\/li>\n<\/ul>\n<p>AstraZeneca is the UK\u2019s largest publicly traded company, but in a sector that\u2019s known for big bets, big wins and big losses, there\u2019s always plenty of room for growth. And that\u2019s especially the case for Astrazeneca, who, despite a market cap of over $170 billion, only just cracks the global top ten when it comes to pharmaceutical company revenue.<\/p>\n<p>But areas for growth are becoming harder to come by. Growth in the US, the UK and Europe is low, and pharmaceutical companies face increased pressure from lawsuits and regulation.<\/p>\n<p>So with that in mind, AstraZeneca appears to be looking east. Specifically, to China. Despite undergoing plenty of economic problems of its own, China still boasts economic growth rates that are the envy of most of the G20.<\/p>\n<p>At the same time, increasing tensions between China, the UK and the US make increasing investment in the country a risk. With grandstanding on both sides about regulatory crackdowns and trade wars, investors are right to be somewhat wary.<\/p>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p>So where does that leave AstraZeneca, and (how) do they plan to continue their push into China?<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">AstraZeneca looks to China for Growth<\/h2>\n<p>So far, it appears that AstraZeneca isn\u2019t too concerned about the geopolitical issues happening between China and the US. They\u2019re already heavily embedded into the country.<\/p>\n<p>Revenue from the country made up 13% of global sales for the company, and the figure of $44 billion makes it the biggest foreign pharmaceutical company in China by revenue.<\/p>\n<p>AstraZeneca\u2019s chair Michel Demar\u00e9 has even gone so far as to state that, \u201cWhen you are a global company like AstraZeneca you have always to cope with geopolitical risk and you have to try to manage that without getting too involved.\u201d<\/p>\n<p>Essentially, if there\u2019s money to be made\u2026<\/p>\n<p>And while China is an attractive target for AstraZeneca due to the potential for new customers, the company also sees it as a hotbed for high quality scientists. Please use the sharing tools found via the share button at the top or side of articles.<\/p>\n<p>\u201cThe innovation power has changed. It is no more \u2018copy, paste\u2019. They really have the power to innovate and put all the money in. There\u2019s a lot of start-ups and we are a part of that\u201d says Demar\u00e9.<\/p>\n<p>There has been a particularly noticeable trend in cancer drug research in China, with the country now accounting for almost 25% of all early-stage cancer drugs globally. That\u2019s up from close to 0% back in 2007.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">Is AstraZeneca spinning off its China business?<\/h2>\n<p>A number of months ago we saw rumors surface that AstraZeneca may be looking to spin off their growing Chinese operations. The company had supposedly created an outline as to what the process would be for ring fencing different components of the company, sheltering it from any tensions that might arise.<\/p>\n<p>The plan would reportedly see AstraZeneca split its holdings in China to a separate legal entity, which would then list on a public market in Asia. The likely landing spot would be Hong Kong or Shanghai stock market, with AstraZeneca UK holding a controlling interest in the company.<\/p>\n<p>In short, they could stay at arms length when it suited them, and still exert control and influence (while taking profits) from the Chinese entity.<\/p>\n<p>So all this sounds like it makes sense, and in many ways it does. Even so, it hasn&#8217;t stopped AstraZeneca themselves from pouring cold water on the idea. In public, at least. And it\u2019s not that hard to see why.<\/p>\n<p>AstraZeneca won\u2019t want to be seen, in any way, to be making any judgment calls or forming any opinions on the rising tensions between China and the US. Leon Wang, AstraZeneca\u2019s, China and international president, categorically ruled out the spinoff speculations as \u201crumor.\u201d<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">The reality of the US\/China situation<\/h2>\n<p>The truth is that it wouldn\u2019t be at all surprising if someone in the risk management department at AstraZeneca has drawn up plans for just this situation. But at this stage, it appears as if these plans are being drawn up to serve as an \u2018emergency eject\u2019 button rather than a long term plan for growth.<\/p>\n<p>AstraZeneca is perfectly able to grow their business in China without operating via a separate Chinese entity. But should tensions get to a point where it could be looking to have a negative impact, having a separation plan already in place is likely to be a major advantage.<\/p>\n<p>And it\u2019s almost surely not just AstraZeneca drawing up plans like these.<\/p>\n<p>Geopolitical risks are a major concern for big multinationals, who have to contend with wide scale operational challenges such as anti-trust lawsuits, broad legislative changes and even wars.<\/p>\n<p>The tensions between China heighten the concern over how it could impact a company\u2019s business, and their bottom line. For investors, these kinds of risks can float under the radar, so it\u2019s important to understand how the companies you hold positions in could be impacted by geopolitical issues.<\/p>\n<p>Of course it also depends on the market segment they\u2019re operating. Any company that poses a cybersecurity risk (e.g. TikTok), or provides advanced warfare capability (Nvidia chips) comes at a higher geopolitical risk. Many companies in this position have long been taking substantial steps to limit this risk.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">The bottom line<\/h2>\n<p>China remains an incredibly attractive market for companies, with an economy that continues to grow and a population that continues to increase their spending power. Even so, it doesn\u2019t come without risks, and the challenges thrown up by the geopolitical environment aren\u2019t to be ignored.<\/p>\n<p>Even so, it appears that AstraZeneca is determined to continue to work to build a foothold in the country. For investors who are prepared to take the risk that comes with the strategy, it could be a recipe for impressive long term success.<\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/qai\/2023\/09\/26\/astrazeneca-looks-to-china-for-growthbut-ceo-says-spinoff-not-happening\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they\u2019re continuing to increase investment in the country Growing tensions between China and the US are making many companies nervous about their operations in China, and AstraZeneca is no exception They\u2019ve reportedly drawn up plans to split their Chinese [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":65586,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-65585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing","tag-featured"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AstraZeneca Looks To China For Growth | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Key Takeaways AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they\u2019re continuing to increase investment in\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=65585\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Looks To China For Growth | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Key Takeaways AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they\u2019re continuing to increase investment in\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=65585\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-26T12:39:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-26T12:39:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/09\/1695731998_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=65585#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=65585\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"AstraZeneca Looks To China For Growth\",\"datePublished\":\"2023-09-26T12:39:57+00:00\",\"dateModified\":\"2023-09-26T12:39:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=65585\"},\"wordCount\":1066,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=65585#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=65585\",\"url\":\"https:\/\/ifintechworld.com\/?p=65585\",\"name\":\"AstraZeneca Looks To China For Growth | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-09-26T12:39:57+00:00\",\"dateModified\":\"2023-09-26T12:39:59+00:00\",\"description\":\"Key Takeaways AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they\u2019re continuing to increase investment in\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=65585#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=65585\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=65585#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Looks To China For Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca Looks To China For Growth | iFintechWorld","description":"Key Takeaways AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they\u2019re continuing to increase investment in","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=65585","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Looks To China For Growth | iFintechWorld","og_description":"Key Takeaways AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they\u2019re continuing to increase investment in","og_url":"https:\/\/ifintechworld.com\/?p=65585","og_site_name":"iFintechWorld","article_published_time":"2023-09-26T12:39:57+00:00","article_modified_time":"2023-09-26T12:39:59+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/09\/1695731998_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=65585#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=65585"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"AstraZeneca Looks To China For Growth","datePublished":"2023-09-26T12:39:57+00:00","dateModified":"2023-09-26T12:39:59+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=65585"},"wordCount":1066,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=65585#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=65585","url":"https:\/\/ifintechworld.com\/?p=65585","name":"AstraZeneca Looks To China For Growth | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-09-26T12:39:57+00:00","dateModified":"2023-09-26T12:39:59+00:00","description":"Key Takeaways AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they\u2019re continuing to increase investment in","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=65585#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=65585"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=65585#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Looks To China For Growth"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/65585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65585"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/65585\/revisions"}],"predecessor-version":[{"id":65587,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/65585\/revisions\/65587"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/65586"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}